Literature DB >> 8961146

Humoral and cellular immunities elicited by HIV-1 vaccination.

J W Shiver1, M E Davies, H C Perry, D C Freed, M A Liu.   

Abstract

Recently it has been shown that immunization with plasmid DNA encoding genes for viral or bacterial antigens can elicit both humoral and cellular immune responses in rodents and nonhuman primates. In this study, mice and nonhuman primates were vaccinated by intramuscular injection with plasmids that express either a secreted form of HIV-1 gp120 or rev proteins. Mice receiving the tPA-gp120 DNA developed antigen-specific antibody responses against recombinant gp120 protein and the V2 peptide neutralization epitope as determined by ELISA. Vaccinated mice also exhibited gp120-specific T cell responses, such as in vitro proliferation of splenocytes and MHC Class I-restricted cytotoxic T lymphocyte (CTL) activities, following antigen restimulation. In addition, supernatants from these lymphocyte cultures showed high levels of gamma-interferon production compared with IL-4, suggesting that primarily type 1-like helper T (Th1) lymphocyte responses were induced by both vaccines. Th1-like responses were also obtained for mice vaccinated with rev DNA. Immune responses induced by gp120 or rev vaccines were dose-dependent, boostable, and long-lived (> or = 6 months). Nonhuman primates vaccinated with tPA-gp120 DNA also showed antigen-specific T lymphocyte proliferative and humoral responses, including moderate levels of neutralizing sera against homologous HIV. These results suggest that plasmid DNA may provide a powerful means for eliciting humoral and cellular immune responses against HIV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961146     DOI: 10.1021/js9600991

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.

Authors:  S Cherpelis; I Shrivastava; A Gettie; X Jin; D D Ho; S W Barnett; L Stamatatos
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.

Authors:  N L Letvin; D C Montefiori; Y Yasutomi; H C Perry; M E Davies; C Lekutis; M Alroy; D C Freed; C I Lord; L K Handt; M A Liu; J W Shiver
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

3.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 4.  A vaccine for HIV type 1: the antibody perspective.

Authors:  D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

5.  Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.

Authors:  D H Barouch; A Craiu; S Santra; M A Egan; J E Schmitz; M J Kuroda; T M Fu; J H Nam; L S Wyatt; M A Lifton; G R Krivulka; C E Nickerson; C I Lord; B Moss; M G Lewis; V M Hirsch; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.

Authors:  M A Egan; W A Charini; M J Kuroda; J E Schmitz; P Racz; K Tenner-Racz; K Manson; M Wyand; M A Lifton; C E Nickerson; T Fu; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene.

Authors:  Danilo R Casimiro; Aimin Tang; Helen C Perry; Romnie S Long; Minchun Chen; Gwendolyn J Heidecker; Mary-Ellen Davies; Daniel C Freed; Natasha V Persaud; Sheri Dubey; Jeffrey G Smith; Diane Havlir; Douglas Richman; Michael A Chastain; Adam J Simon; Tong-Ming Fu; Emilio A Emini; John W Shiver
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

8.  Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys.

Authors:  D H Barouch; A Craiu; M J Kuroda; J E Schmitz; X X Zheng; S Santra; J D Frost; G R Krivulka; M A Lifton; C L Crabbs; G Heidecker; H C Perry; M E Davies; H Xie; C E Nickerson; T D Steenbeke; C I Lord; D C Montefiori; T B Strom; J W Shiver; M G Lewis; N L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies.

Authors:  M J Hosie; J N Flynn; M A Rigby; C Cannon; T Dunsford; N A Mackay; D Argyle; B J Willett; T Miyazawa; D E Onions; O Jarrett; J C Neil
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.